Matt Hewitt
Stock Analyst at Craig-Hallum
(2.67)
# 1,906
Out of 4,902 analysts
40
Total ratings
51.35%
Success rate
3.91%
Average return
Main Sectors:
Stocks Rated by Matt Hewitt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLP Simulations Plus | Maintains: Buy | $45 → $36 | $12.46 | +188.92% | 8 | Jun 13, 2025 | |
| CSBR Champions Oncology | Maintains: Buy | $8 → $12 | $7.97 | +50.56% | 4 | Mar 12, 2025 | |
| CLOV Clover Health Investments | Initiates: Buy | $6 | $2.94 | +104.08% | 1 | Dec 17, 2024 | |
| BLFS BioLife Solutions | Maintains: Buy | $30 → $32 | $20.83 | +53.62% | 4 | Nov 13, 2024 | |
| OMCL Omnicell | Maintains: Buy | $45 → $64 | $26.88 | +138.10% | 6 | Oct 31, 2024 | |
| NOTV Inotiv | Maintains: Buy | $25 → $10 | $1.75 | +471.43% | 3 | May 16, 2024 | |
| SDGR Schrödinger | Maintains: Buy | $35 → $30 | $21.45 | +39.86% | 3 | May 2, 2024 | |
| MXCT MaxCyte | Initiates: Buy | $7 | $2.03 | +245.68% | 1 | Nov 29, 2023 | |
| RGEN Repligen | Maintains: Buy | $207 → $200 | $116.25 | +72.04% | 3 | Aug 3, 2023 | |
| OABI OmniAb | Initiates: Buy | $10 | $1.96 | +411.51% | 1 | Apr 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $67 → $30 | $8.05 | +272.67% | 5 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $400 | $1.08 | +37,109.30% | 1 | Jan 4, 2022 |
Simulations Plus
Jun 13, 2025
Maintains: Buy
Price Target: $45 → $36
Current: $12.46
Upside: +188.92%
Champions Oncology
Mar 12, 2025
Maintains: Buy
Price Target: $8 → $12
Current: $7.97
Upside: +50.56%
Clover Health Investments
Dec 17, 2024
Initiates: Buy
Price Target: $6
Current: $2.94
Upside: +104.08%
BioLife Solutions
Nov 13, 2024
Maintains: Buy
Price Target: $30 → $32
Current: $20.83
Upside: +53.62%
Omnicell
Oct 31, 2024
Maintains: Buy
Price Target: $45 → $64
Current: $26.88
Upside: +138.10%
Inotiv
May 16, 2024
Maintains: Buy
Price Target: $25 → $10
Current: $1.75
Upside: +471.43%
Schrödinger
May 2, 2024
Maintains: Buy
Price Target: $35 → $30
Current: $21.45
Upside: +39.86%
MaxCyte
Nov 29, 2023
Initiates: Buy
Price Target: $7
Current: $2.03
Upside: +245.68%
Repligen
Aug 3, 2023
Maintains: Buy
Price Target: $207 → $200
Current: $116.25
Upside: +72.04%
OmniAb
Apr 13, 2023
Initiates: Buy
Price Target: $10
Current: $1.96
Upside: +411.51%
Apr 28, 2022
Maintains: Hold
Price Target: $67 → $30
Current: $8.05
Upside: +272.67%
Jan 4, 2022
Initiates: Buy
Price Target: $400
Current: $1.08
Upside: +37,109.30%